Earnings summaries and quarterly performance for Voyager Therapeutics.
Executive leadership at Voyager Therapeutics.
Board of directors at Voyager Therapeutics.
Research analysts who have asked questions during Voyager Therapeutics earnings calls.
Jack Allen
Robert W. Baird & Co.
4 questions for VYGR
Jay Olson
Oppenheimer & Co. Inc.
4 questions for VYGR
Mehdi Goudarzi
Truist Securities
3 questions for VYGR
Patrick Trucchio
H.C. Wainwright & Co.
3 questions for VYGR
Philip Nadeau
TD Cowen
3 questions for VYGR
Ry Forseth
Guggenheim Securities
3 questions for VYGR
Sumant Kulkarni
Canaccord Genuity
3 questions for VYGR
Joon Lee
Truist Securities
2 questions for VYGR
Laura Chico
Wedbush Securities
2 questions for VYGR
Lili Nsongo
iA Capital Markets
2 questions for VYGR
Yanan Zhu
Wells Fargo Securities
2 questions for VYGR
David Hoang
Citigroup
1 question for VYGR
Divya Rao
TD Cowen
1 question for VYGR
Kuan-Hung Lin
Wells Fargo
1 question for VYGR
Pete Stavropoulos
Cantor Fitzgerald
1 question for VYGR
Samantha Semenkow
Citigroup Inc.
1 question for VYGR
Shawn
Citigroup
1 question for VYGR
Recent press releases and 8-K filings for VYGR.
- Voyager Therapeutics anticipates 2026 to be a pivotal year, focusing on three principal pillars: advancing tau-targeting programs, validating brain-targeted capsids in humans, and demonstrating the value of its NeuroShuttle™ platform.
- Key milestones for 2026 include expected first-in-human dosing for VY1706 (tau silencing gene therapy) in H2 2026, initial tau PET imaging data for VY7523 (anti-tau antibody) in H2 2026, and clinical trial initiation for Neurocrine's NBIB-'223 for Friedreich's ataxia.
- The company projects a cash runway into 2028, which does not account for $6.8 billion in potential milestone payments from existing partnerships.
- Voyager Therapeutics is a multimodality neurotherapeutics company focused on optimizing delivery for neurological diseases, leveraging gene therapy and shuttle platforms.
- The company's Phase 1 anti-TAU antibody program for Alzheimer's disease is expected to have a readout in 2026. This antibody demonstrated a 70% effect in blocking TAU spread in an animal model, differentiating it from prior failed N-terminal antibodies, and Voyager intends to seek a partner for Phase 3.
- Voyager anticipates its TAU silencing gene therapy (1706), which utilizes an ALPL-utilizing capsid for efficient blood-brain barrier penetration, to enter the clinic in 2026.
- The company maintains multiple partner programs with Neurocrine, Novartis, and AstraZeneca, and is developing gene therapies for Friedreich's ataxia, GBA1-related Parkinson's/Gaucher's, and APOE-related Alzheimer's, alongside a small molecule program for TDP-43 in ALS.
- Voyager Therapeutics reported a net loss of $27.9 million for the third quarter of 2025, compared to $9.0 million for the same period in 2024, with collaboration revenue decreasing to $13.4 million from $24.6 million.
- The company ended the third quarter of 2025 with $229 million in cash, cash equivalents, and marketable securities, maintaining its cash runway into 2028.
- Key operational updates include a $3 million milestone payment expected from Neurocrine Biosciences in Q4 2025, the introduction of the Voyager NeuroShuttle™ discovery program, and a new collaboration with Transition Bio for small molecules targeting TDP-43 with potential milestone payments up to $500 million. Novartis also discontinued two discovery-stage programs, with rights returning to Voyager.
Quarterly earnings call transcripts for Voyager Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more